SEC Form 4 · accession 0001209191-19-009663
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey M Leiden
Officer — CEO & President · Director
Period of report
Feb 11, 2019
Accepted (ET)
Feb 13, 2019 · 4:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Feb 11, 2019 | S | 14,707 | $179.28 | D | 223,916 | D | |
| Common StockF3,F4 | Feb 11, 2019 | S | 47,661 | $179.93 | D | 176,255 | D | |
| Common StockF3,F5 | Feb 11, 2019 | S | 48,651 | $180.81 | D | 127,604 | D | |
| Common StockF2,F6 | Feb 11, 2019 | S | 412 | $181.80 | D | 127,192 | D | |
| Common Stock | holding | — | — | — | 440 | I | 401(k) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $179.28 (range $178.47 to $179.47).
- F3Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $179.93 (range $179.48 to $180.47).
- F5Open market sales reported on this line occurred at a weighted average price of $180.81 (range $180.48 to $181.45).
- F6Open market sales reported on this line occurred at a weighted average price of $181.80 (range $181.52 to $181.81).